– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million […]
Events
London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, today announces the publication of two papers in key scientific […]
11 March 2021
London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening lung infections, is pleased to announce that the company was […]
26 October 2020
London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that company scientists gave 4 […]
02 March 2020
We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting […]
26 April 2019
Fungal Update Meeting This is the first report describing the use of PC945 treatment for refractory Aspergillus bronchial anastomotic infection and tracheobronchitis in a lung transplant patient. Treatment was highly […]
02 March 2019
Pulmocide presented two posters at the recent 8th Advances Against Aspergillosis Conference, held February 1-3, 2018 in Lisbon, Portugal. There are as follow A full copy of the scientific posters […]
16 February 2018
Pulmocide and PGIMER (Chandigarh, India) presented one poster at the recent 8th Trends in Medical Mycology Conference, held November 6-9, 2017 in Belgrade, Serbia. There are as follow A full […]
16 February 2018
Pulmocide is pleased to announce another PC945 publication in Antimicrobial Agents and Chemotherapy. The publication is available to download from the link below: AAC.ASM.ORG or the PDF can be downloaded […]
03 July 2017
Pulmocide gave an oral presentation at Annual Conference of Microbiology society 2017, held on April 02-06, 2017 in Edinburgh in UK. Title was: Preclinical characterization of PC786, a novel inhaled […]
26 April 2017